E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedMachine draft
Standard · 3 min
Management of Fibromyalgia: Novel Nutraceutical Therapies Beyond Traditional Pharmaceuticals.
Antonelli, Antonella, Bianchi, Marzia, Fear, Elizabeth Jane et al. · Nutrients · 2025 · DOI
Quick Summary
This review examines how natural plant-based compounds, particularly polyphenols, might help manage fibromyalgia pain without the side effects of traditional medications. Fibromyalgia and ME/CFS are related conditions that involve abnormal pain signaling in the nervous system, persistent fatigue, and sleep problems. The authors suggest that natural products could be safer alternatives to current drugs like antidepressants and anticonvulsants, which can cause dependence and tolerance over time.
Why It Matters
ME/CFS patients experience similar central nervous system-mediated symptoms to fibromyalgia and often suffer adverse effects from standard psychiatric medications. This review highlights the potential for natural compounds to address pain and fatigue while avoiding dependence and tolerance—concerns particularly relevant to the ME/CFS population, which frequently reports medication intolerance. Exploring alternative management strategies is critical given the limited effectiveness of current pharmaceutical approaches in CSS conditions.
Observed Findings
Fibromyalgia and ME/CFS share common pathophysiologic features including abnormal central pain processing, endogenous analgesia defects, and neuroendocrine dysregulation.
Polyphenols demonstrate anti-inflammatory and antinociceptive properties in preclinical models of neuropathic pain.
Current pharmaceutical treatments (antidepressants, anticonvulsants) carry risks of physical dependence, tolerance, and significant adverse effects.
Traditional anti-inflammatory agents (corticosteroids, NSAIDs) show limited efficacy for fibromyalgia when inflammatory mechanisms are not prominent.
Central sensitivity syndrome represents a unifying diagnostic framework encompassing fibromyalgia, ME/CFS, migraine, and irritable bowel syndrome.
Inferred Conclusions
Natural polyphenols and bioavailable phytochemicals represent a promising avenue for developing safer, non-dependent analgesic therapies for central sensitivity syndromes including fibromyalgia and ME/CFS.
The adverse effect profile and tolerance development associated with current pharmacotherapy supports investigation of alternative approaches.
Multiple mechanisms—anti-inflammatory, antinociceptive, and neuromodulatory—suggest polyphenols may address the complex pathophysiology of CSS.
Remaining Questions
Which specific polyphenols and natural compounds demonstrate the greatest efficacy and bioavailability in human clinical trials for fibromyalgia and ME/CFS?
What This Study Does Not Prove
This narrative review does not provide direct clinical evidence that specific nutraceuticals effectively treat ME/CFS or fibromyalgia in humans; it is a theoretical framework rather than a systematic analysis of clinical trial data. The review does not demonstrate causation between polyphenol use and symptom improvement, nor does it establish superiority over existing treatments. Individual patient responses to natural products vary significantly, and the bioavailability and safety of specific compounds remain incompletely characterized.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →